Literature DB >> 19494353

WT1 mutations in T-ALL.

Valeria Tosello1, Marc R Mansour, Kelly Barnes, Maddalena Paganin, Maria Luisa Sulis, Sarah Jenkinson, Christopher G Allen, Rosemary E Gale, David C Linch, Teresa Palomero, Pedro Real, Vundavalli Murty, Xiaopan Yao, Susan M Richards, Anthony Goldstone, Jacob Rowe, Giuseppe Basso, Peter H Wiernik, Elisabeth Paietta, Rob Pieters, Martin Horstmann, Jules P P Meijerink, Adolfo A Ferrando.   

Abstract

The molecular mechanisms involved in disease progression and relapse in T-cell acute lymphoblastic leukemia (T-ALL) are poorly understood. We used single nucleotide polymorphism array analysis to analyze paired diagnostic and relapsed T-ALL samples to identify recurrent genetic alterations in T-ALL. This analysis showed that diagnosis and relapsed cases have common genetic alterations, but also that relapsed samples frequently lose chromosomal markers present at diagnosis, suggesting that relapsed T-ALL emerges from an ancestral clone different from the major leukemic population at diagnosis. In addition, we identified deletions and associated mutations in the WT1 tumor suppressor gene in 2 of 9 samples. Subsequent analysis showed WT1 mutations in 28 of 211 (13.2%) of pediatric and 10 of 85 (11.7%) of adult T-ALL cases. WT1 mutations present in T-ALL are predominantly heterozygous frameshift mutations resulting in truncation of the C-terminal zinc finger domains of this transcription factor. WT1 mutations are most prominently found in T-ALL cases with aberrant rearrangements of the oncogenic TLX1, TLX3, and HOXA transcription factor oncogenes. Survival analysis demonstrated that WT1 mutations do not confer adverse prognosis in pediatric and adult T-ALL. Overall, these results identify the presence of WT1 mutations as a recurrent genetic alteration in T-ALL.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19494353      PMCID: PMC2721784          DOI: 10.1182/blood-2008-12-192039

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

1.  Dominant-negative mutations of the Wilms' tumour predisposing gene (WT1) are infrequent in CML blast crisis and de novo acute leukaemia.

Authors:  M Carapeti; J M Goldman; N C Cross
Journal:  Eur J Haematol       Date:  1997-05       Impact factor: 2.997

2.  A dominant mutation in the Wilms tumor gene WT1 cooperates with the viral oncogene E1A in transformation of primary kidney cells.

Authors:  D A Haber; H T Timmers; J Pelletier; P A Sharp; D E Housman
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

3.  COBRA: a sensitive and quantitative DNA methylation assay.

Authors:  Z Xiong; P W Laird
Journal:  Nucleic Acids Res       Date:  1997-06-15       Impact factor: 16.971

Review 4.  A clinical overview of WT1 gene mutations.

Authors:  M Little; C Wells
Journal:  Hum Mutat       Date:  1997       Impact factor: 4.878

5.  Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance.

Authors:  L King-Underwood; K Pritchard-Jones
Journal:  Blood       Date:  1998-04-15       Impact factor: 22.113

6.  Nonhereditary p53 mutations in T-cell acute lymphoblastic leukemia are associated with the relapse phase.

Authors:  M H Hsiao; A L Yu; J Yeargin; D Ku; M Haas
Journal:  Blood       Date:  1994-05-15       Impact factor: 22.113

7.  Mutations in the Wilms' tumor gene WT1 in leukemias.

Authors:  L King-Underwood; J Renshaw; K Pritchard-Jones
Journal:  Blood       Date:  1996-03-15       Impact factor: 22.113

8.  TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms.

Authors:  L W Ellisen; J Bird; D C West; A L Soreng; T C Reynolds; S D Smith; J Sklar
Journal:  Cell       Date:  1991-08-23       Impact factor: 41.582

9.  DNA binding capacity of the WT1 protein is abolished by Denys-Drash syndrome WT1 point mutations.

Authors:  M Little; G Holmes; W Bickmore; V van Heyningen; N Hastie; B Wainwright
Journal:  Hum Mol Genet       Date:  1995-03       Impact factor: 6.150

10.  Evidence that WT1 mutations in Denys-Drash syndrome patients may act in a dominant-negative fashion.

Authors:  M H Little; K A Williamson; M Mannens; A Kelsey; C Gosden; N D Hastie; V van Heyningen
Journal:  Hum Mol Genet       Date:  1993-03       Impact factor: 6.150

View more
  58 in total

1.  Acute lymphoblastic leukemia of adulthood: progress or not?

Authors:  Peter H Wiernik
Journal:  Curr Treat Options Oncol       Date:  2011-12

2.  Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia.

Authors:  Sandra Heesch; Nicola Goekbuget; Andrea Stroux; Jutta Ortiz Tanchez; Cornelia Schlee; Thomas Burmeister; Stefan Schwartz; Olga Blau; Ulrich Keilholz; Antonia Busse; Dieter Hoelzer; Eckhard Thiel; Wolf-Karsten Hofmann; Claudia D Baldus
Journal:  Haematologica       Date:  2010-04-30       Impact factor: 9.941

3.  Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia.

Authors:  Alejandro Gutierrez; Suzanne E Dahlberg; Donna S Neuberg; Jianhua Zhang; Ruta Grebliunaite; Takaomi Sanda; Alexei Protopopov; Valeria Tosello; Jeffery Kutok; Richard S Larson; Michael J Borowitz; Mignon L Loh; Adolfo A Ferrando; Stuart S Winter; Charles G Mullighan; Lewis B Silverman; Lynda Chin; Stephen P Hunger; Stephen E Sallan; A Thomas Look
Journal:  J Clin Oncol       Date:  2010-07-19       Impact factor: 44.544

4.  Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor.

Authors:  Richard D Williams; Reem Al-Saadi; Tasnim Chagtai; Sergey Popov; Boo Messahel; Neil Sebire; Manfred Gessler; Jenny Wegert; Norbert Graf; Ivo Leuschner; Mike Hubank; Chris Jones; Gordan Vujanic; Kathy Pritchard-Jones
Journal:  Clin Cancer Res       Date:  2010-03-23       Impact factor: 12.531

5.  The NOTCH signaling pathway: role in the pathogenesis of T-cell acute lymphoblastic leukemia and implication for therapy.

Authors:  Valeria Tosello; Adolfo A Ferrando
Journal:  Ther Adv Hematol       Date:  2013-06

6.  Mutations of NOTCH1, FBXW7, and prognosis in T-lineage acute lymphoblastic leukemia.

Authors:  Charles G Mullighan
Journal:  Haematologica       Date:  2009-10       Impact factor: 9.941

7.  Mutations of PHF6 are associated with mutations of NOTCH1, JAK1 and rearrangement of SET-NUP214 in T-cell acute lymphoblastic leukemia.

Authors:  Qian Wang; Huiying Qiu; Hui Jiang; Lili Wu; Shasha Dong; Jinlan Pan; Wenjuan Wang; Nana Ping; Jing Xia; Aining Sun; Depei Wu; Yongquan Xue; Hans G Drexler; Roderick A F Macleod; Suning Chen
Journal:  Haematologica       Date:  2011-08-31       Impact factor: 9.941

8.  Poor Response to Standard Chemotherapy in Early T-precursor (ETP)-ALL: A Subtype of T-ALL Associated with Unfavourable Outcome: A Brief Report.

Authors:  Nida Iqbal; Atul Sharma; Vinod Raina; Lalit Kumar; Sameer Bakhshi; Rajive Kumar; Smeeta Gajendra
Journal:  Indian J Hematol Blood Transfus       Date:  2014-01-19       Impact factor: 0.900

Review 9.  Can one target T-cell ALL?

Authors:  Adolfo Ferrando
Journal:  Best Pract Res Clin Haematol       Date:  2018-10-17       Impact factor: 3.020

10.  Advances in the Biology of Acute Lymphoblastic Leukemia-From Genomics to the Clinic.

Authors:  Charles G Mullighan; Cheryl L Willman
Journal:  J Adolesc Young Adult Oncol       Date:  2011-06       Impact factor: 2.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.